Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ovarian Neoplasms

Free Subscription 15.06.2026 6 Gynecol Oncol 1 Histopathology 1 J Natl Cancer Inst 1 Oncogene 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Gynecol Oncol

1. TANG X, Huang H, Peipert JD, Zola A, et al
   Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.
   Gynecol Oncol. 2026;210:174-182.
   PubMed         Abstract available
   
   
2. KARLSEN NS, Hogdall CK, Dreisler E, Sakse AE, et al
   Adding HE4 to the IOTA ADNEX model for differentiating adnexal masses: A Danish prospective, multicenter study.
   Gynecol Oncol. 2026;209:111-119.
   PubMed         Abstract available
   
   
3. ZHANG X, Shahryari J, Kingsley LG, McCluggage WG, et al
   Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract.
   Gynecol Oncol. 2026;209:62-68.
   PubMed         Abstract available
   
   
4. GRUBE M, Ribeiro de Souza B, Neilson A, Tinker A, et al
   Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.
   Gynecol Oncol. 2026;209:48-55.
   PubMed         Abstract available
   
   
5. LUDMIR D, Huang Y, Xu X, Dioun S, et al
   Impact of lymphadenectomy on survival outcomes for stage I malignant ovarian germ cell tumors.
   Gynecol Oncol. 2026;209:40-47.
   PubMed         Abstract available
   
   
6. CAGDAS EK
   Pathway-level somatic mutation burden reflects diffuse genomic accumulation rather than selective transcriptional disruption in ovarian serous carcinoma: Evidence from bulk, spatial, and multi-region genomic analyses.
   Gynecol Oncol. 2026;209:7-14.
   PubMed         Abstract available
   
   

   
   Histopathology

7. LIN W, Zhou X, Wang Y, Zhou F, et al
   Malignant struma ovarii: Advances in molecular pathogenesis, classification, diagnosis and treatment.
   Histopathology. 2026;89:26-46.
   PubMed         Abstract available
   
   

   
   J Natl Cancer Inst

8. CARBONE A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, et al
   Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer.
   J Natl Cancer Inst. 2025 Aug 28:djaf250. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Oncogene

9. SUNDARARAJAN V, Ziyu F, Elfar GA, Tan TZ, et al
   Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition.
   Oncogene. 2026 Jun 11. doi: 10.1038/s41388-026-03830.
   PubMed         Abstract available
   
   

   
   PLoS One

10. CHEN S, Yang X, Jiang S, Lin Y, et al
    Burden and temporal trends of female-specific cancers in China: A systematic analysis of the 2023 global burden of disease study.
    PLoS One. 2026;21:e0351539.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

11. LI R, Huang X, Chen Y, Chen X, et al
    GREM1/FGFR1-activated myofibroblasts induce immunosuppression and accelerate metastasis in high-grade serous ovarian cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2529786123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum